Following my earlier post on this issue, it is now reported that the Indian Patent Office (IPO) has refused patent to the anti-cancer drug, Abraxane. I am yet to obtain a copy of this IPO order.
A recap
Briefly, the opposition against the patent application for Abraxane was filed by Natco Pharma with the IPO and was decided against the patent applicant, Abraxis Biosciences (“Abraxis”). Abraxis appealed against the IPO’s order with the Intellectual Property Appellate Board (IPAB) owing to certain procedural lapses. IPAB agreed with Abraxis and asked the IPO to consider the opposition afresh.
What’s new?
The recent order of the IPO is said to have stated the following:
“The amended claims (here Abraxis Boisciences) lack inventive step and do not constitute an invention under the Patents Act, 1970.”
I will update this post and discuss the IPO’s order in detail once I peruse the order.
Raja Selvam
Founder & Managing Attorney, Selvam & Selvam | Practice areas include Trademarks, Patents, Domain names & Business law. Visiting faculty, Department of Journalism, Madras University where I teach copyrights & trademarks law. Passionate about entrepreneurship, start-ups, stocks, farming, technology and law.
The Curious Case of two Copied Patents and the Novelty of Transparency
The Calcutta High Court, in November had the opportunity to deal with a rather interesting patent dispute where one person tried invalidating a…
Tirunelveli or Irruttukadai Halwa – GI or Trademark
The year 2014 has witnessed a lot of goods entering the family of Geographical Indicators ( GI ). Goods such as Madurai Malli (jasmine), Pattamadai…
Trademark Injunctions and Damages in India – Part Three
In my earlier posts (here and here), I discussed the position of law on injunctions, the requirements for grant of temporary injunction and relevant…